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HepG2/C3A 3D spheroids exhibit stable physiological
functionality for at least 24 days after recovering from
trypsinisation
Krzysztof Wrzesinski,†a Maria Chiara Magnone,†b Line Visby Hansen,c
Marianne Ehrhorn Kruse,d Tobias Bergauer,e Maria Bobadilla,b Marcel Gubler,b
Jacques Mizrahi,b Kelan Zhang,d Christina M. Andreasen,f Kira Eyð Joensen,a
Signe Marie Andersen,a Jacob Bastholm Olesen,a Ove B. Schaﬀalitzky de Muckadellg
and Stephen J. Fey*a
Primary human hepatocytes are widely used as an in vitro system for the assessment of drug metabolism
and toxicity. Nevertheless a cell system with higher stability of physiological functions is required for the
investigation of drugs’ mode of action, pathway analyses and biomarkers evaluations. We recently dis-
covered that the human hepatocellular carcinoma cell line, HepG2/C3A, cultured as spheroids in a 3D system
can recover their main functions after trypsinisation within about 18 days. The objective of this study was
to investigate whether the spheroids’ metabolic functions remained stable after this recovery period.
Therefore we evaluated physiological capabilities of the spheroids (cell survival, growth rate, glycogen-
esis, ATP, cholesterol and urea synthesis and drug metabolism) and the expression of key genes related to
the main liver pathways in spheroids cultured for an additional 24 days after full recovery (day 18). Here
we show that after the recovery period, the 3D spheroid culture can provide a metabolically competent
homeostatic cell model which is in equilibrium with its culture environment for more than 3 weeks. Such
a stable system could be used for the assessment of the drugs’ mode of action, for biomarkers evaluation
and for any systems biology studies which require medium- to long-term stability of metabolic functions.
Introduction
The liver is a central organ for drug metabolism and therefore
in vitro hepatocytes models (both primary cells and cell lines)
are widely used for evaluating the safety and eﬃcacy of com-
pounds and their mode of action on specific pathways. These
studies have illustrated that primary hepatocytes have limited
stability in their physiological functions in vitro, and that hep-
atocyte cell lines do not fully reflect liver functions.1–3 An
in vitro system is required that recapitulates liver functions
in vitro and that maintains those functions for a suﬃcient
amount of time for testing the mid- and long-term eﬀects of
compounds.
In a recent study, we compared cells grown in a classical 2D
cell culture and 3D spheroid formats in otherwise identical
culture conditions. We reported that the 3D spheroid culture
systems allow cells to recover from trypsinisation and re-
establish their advanced functions (such as cellular organis-
ation, cholesterol and urea synthesis and cytochrome P450
expression) within 15–18 days. During the recovery process,
the cells in the spheroids are engaged in re-establishment of
their key functions and their growth rate slows down. The cells
undergo a clear transition approximately 18 days after culture
initiation after which the cell activities stabilise. Before tran-
sition the amounts of ATP, urea, cholesterol and adenylate
kinase all increase. After the transition, the amounts of†These authors equally contributed to the study.
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adenylate kinase and cholesterol secreted fall while ATP and
urea increase (at least up to day 21 at which timepoint that
study was ended).4
In this study we investigate the question as to whether the
cell functions recovered after the first 21 days in culture are
maintained from day 21 to day 42. Few studies have followed
the physiological capacity of immortal cells for six weeks post
trypsinisation and investigated whether the 3D spheroid
system is able to respond to physiological and pharmacologi-
cal stimulations in a way that reproduces in vivo liver
functions.
The parameters that have been investigated in this study
were general cell viability (growth rate, ATP synthesis and
adenylate kinase release), basal physiological capacity as illus-
trated by glucose metabolism, urea production, cholesterol
synthesis and response to pharmacological treatment (inhi-
bition of cholesterol production by lovastatin). We have also
evaluated the expression of key genes involved in the liver
functions under evaluation (e.g. glycogen and glucose meta-
bolism, cholesterol synthesis, urea cycle, bile acids synthesis
and transport) to confirm the stability of the molecular path-
ways behind the physiological functions.
All of these assays, without exception, demonstrate that,
once the spheroids have passed through the transition (which
occurs about 15–18 days after culture initiation), they exhibit a
very stable functionality for at least a further 24 days. Thus 3D
spheroids cultivated in the microgravity ProtoTissue™ bio-
reactor provide a biological system ‘at rest’ or in equilibrium
where a minimum of background ‘noise’ from extraneous
cellular processes is of value. The spheroid system provides a
useful tool for drug discovery for understanding compounds’
mode of action and for the evaluation of pharmacodynamics
and/or mechanistic biomarkers.
Materials and methods
For the sake of comparability, spheroid preparation and deter-
mination of growth, protein content, ATP, urea, cholesterol
and glycogen were carried out by following exactly the same
procedures as reported previously.4
Standard culture conditions
The immortal human hepatocellular carcinoma cell line,
HepG2/C3A (ATCC CRL-10741), was grown in standard tissue
culture conditions (D-MEM (containing 1 g glucose L−1)).
Spheroid culture conditions (3D culture)
Preparation of spheroids using AggreWell™ plates. The
HepG2/C3A cell spheroids were prepared using AggreWell™
400 plates (Stemcel Technologies cat. no. 27845) as previously
described.
Spheroid culture in ProtoTissue™ bioreactors. The Proto-
Tissue™ bioreactor (MC2 Biotek, Hørsholm, cat. no. 010)
humidity chamber was filled with distilled sterile water, and
the growth chamber was prewetted with growth medium for
24 h before use by rotating in the incubator. Spheroids were
detached from the AggreWell™ plates, visually selected on the
basis of their quality (compactness, size and roundness) and
placed in the ProtoTissue™ bioreactors. The spheroids were
cultivated at 37 °C, 5% CO2, 95% air for a minimum of
21 days, exchanging the medium every two to three days.5,6
Culture in serum-free media. Spheroids do not grow well in
serum-free media. Therefore, for the analysis of urea and
cholesterol production and gene expression, spheroids were
normally grown in standard media but this was temporarily
exchanged with serum-free media 24 hours before sample col-
lection or RNA isolation.
Protein determination in spheroids
The amount of protein present in a sample was determined
using the fluorescence-based ProStain Protein Quantification
Kit (Active Motif Inc., cat. no. 15001). There were duplicate bio-
logical replicates and nine technical replicates.
Growth rate and protein content estimation in spheroids
Spheroids were photographed on days 1, 3, 6, 8, 10, 13, 15, 17,
21, 25, 34 and 42 post culture initiation and the area of on
average 181 spheroids measured individually at each time
point and used to calculate the protein content of the
spheroid. Briefly photomicrographs were taken using an
Olympus IX81 motorized microscope and an Olympus DP71
camera. The ‘shadow’ area of spheroids was measured using
the ‘Fitted Polygon Area’ function.6
ATP assay for cell viability
Samples of the hepatocytes grown as spheroids (usually 6–2
spheroids per assay point depending on the age of the culture)
were collected and cell viability was measured using the Cell-
Titer-Glo luminescent cell viability assay (Promega, cat. no.
G7571). The data were normalized with reference to a standard
curve for ATP, to the untreated control and to the amount of
cellular protein present.
Adenylate kinase assay for cell viability
Adenylate kinase in spent media was measured using the bio-
luminescent cytotoxicity assay kit (Lonza Toxilight assay kit,
cat. no. LT07-117). Media from spheroid cultures were col-
lected in triplicate in connection with refreshing the growth
media (typically at 48 h intervals).
Glycogen synthesis in basal and insulin-stimulated conditions
Spheroids were serum starved for 20 h in DMEM with 5.5 mM
glucose, 0.1% fatty acid free-BSA, 10 mM HEPES and
50 IU ml−1 penicillin–streptomycin. After starvation, the
medium was completely aspirated, a small sample of spheroids
was used for quality assessment and Trypan Blue staining to
ensure that the viability was still >95%. The remaining spher-
oids were divided into 18 separate bioreactors (approximately
30 mg wet weight spheroids/bioreactor). Spheroids were
treated with 0 or 100 nM Humulin® in either DMEM with 5.5
or 11.1 mM glucose containing 1.6 or 3.2 μCi ml−1 D-[U-14C]-
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glucose respectively and cultivated for 2.5 h. Experiments were
set up in quadruplicate, except for the blank control samples
(where no radioactivity was added) that was set up in dupli-
cate. After treatment, spheroids were washed three times in
37 °C PBS and lysed in 30% KOH by shaking. After
15 minutes, an equal volume of double distilled H2O was
added. A small aliquot was withdrawn from each cell lysate
and used for protein determination by the Bradford method.7
Cell lysates were incubated at 95 °C for 1 h and then cooled
in ice. 2 mg unlabeled glycogen and 1 ml 95% ethanol were
added to each sample and they were left overnight at −20 °C to
precipitate the glycogen. Samples were spun at 12 500g for
10 minutes and the supernatant was aspirated. Precipitates
were solubilized by shaking in formic acid. 1 ml OptiPhase
Hisafe 2 liquid scintillation cocktail was added and samples
were mixed thoroughly. The amount of radioactive material in
each sample was quantified using a Wallac 1450 microbeta
scintillation counter. The glycogen content of the individual
samples was related to their total protein content.
In a parallel experiment, the influence of the glucose con-
centration in the media was investigated. The above procedure
was repeated except that the incubation was carried out in
DMEM with 5.5, 11.1 or 25 mM glucose containing 1.6, 3.2 or
7.3 μCi ml−1 D-[U-14C]-glucose respectively and cultivated for
2.5 h. No additional insulin was added.
Urea assay
Urea was measured using the Urea Assay Kit (Biovision, cat.
no. K375-100) according to the manufacturer’s instructions.
Briefly, samples of growth media from duplicate cultures
spheroids were centrifuged to remove any cellular debris and
used for urea determination. A standard curve was prepared
in the same way for each assay plate using a urea standard
(Biovision, cat. no. 700623).
Cholesterol assay
Cholesterol in the spent media was measured using the
Amplex Red Cholesterol Assay Kit (Invitrogen, cat. no. A12216)
according to the manufacturer’s instructions with slight modi-
fications. Positive, negative and standard curves were added to
each reading plate.
Gene expression
RNA was purified using the RNeasy Minikit cat. no. 74104 and
RNase-Free DNase Set cat. no. 79254 both from Qiagen accord-
ing to the manufacturer’s instructions. Cells in the spheroids
were disrupted by adding 350 μl ‘RLT buﬀer’ plus 350 μl 70%
ethanol and vortexing. The sample was then transferred to the
RNeasy column and centrifuged at 8000g for 15 s at room
temperature. RNase free DNase 1 (80 μl) was added to the
column and incubated at room temperature for 15 min. The
column was then washed by adding 350 μl RLT buﬀer and cen-
trifuged at 8000g for 15 s at room temperature. This was
repeated with ‘RPE buﬀer’ (500 μl) twice where the second
spin was prolonged to 2 min. Following this the RNeasy
column was transferred to a new microtube and centrifuged at
11 000g for 1 min. The RNeasy column was once again trans-
ferred to a new microtube and the RNA was eluted by adding
50 μl H2O and centrifuged at 8000g for 1 min. The elution
wash was repeated once and the eluate was pooled. Absor-
bance was measured at 230, 260 and 280 nm in a spectropho-
tometer and the quality was approved if the ratios 260/280 and
260/230 were both greater than 1.8.
Reverse transcription of RNA was accomplished using the
SuperScript III First-Strand Synthesis Kit (Invitrogen) accord-
ing to the manufacturer’s protocol with a total RNA input of
100 ng per reaction. cDNA samples were then diluted 1 : 3 in
TE buﬀer and 14 cycles of pre-amplification were carried out
using 2× TaqMan PreAmp Master Mix (Applied Biosystems)
and pooled Taqman Assays (Applied Biosystems) at a final con-
centration of 0.2× per assay. The following thermocycler
program was used: 95 °C for 10 min, followed by 14 cycles at
95 °C for 15 s and 60 °C for 4 min. Pre-amplified cDNA pro-
ducts were diluted 1 : 5 in TE buﬀer. qPCR was performed
using the 96.96 dynamic array (Fluidigm Corporation, CA,
USA) following the manufacturer’s protocol (Fluidigm Quick
Reference Card, PN 68000130, Rev. B). Briefly, for each sample
a 5 μl sample mix was prepared with 1× GE Sample Loading
Reagent (Fluidigm), 1× Taqman Gene Expression Mastermix
(Applied Biosystems) and diluted, pre-amplified cDNA. For the
assay mix 1× Assay Loading Reagent (Fluidigm) was mixed
with each of the Taqman Assays (final concentration: 10×),
respectively. Priming of the Fluidigm array with a control line
fluid and mixing of the sample and assay reagents were done
with an IFC controller. qPCR was performed using a BioMark
Instrument with the following cycling parameters: 95 °C for
10 min, followed by 40 cycles at 95 °C for 15 s and 60 °C for
1 min. Data were collected and analyzed with Real-Time PCR
Analysis Software (Fluidigm Corporation, CA, USA).
Inhibition of cholesterol synthesis by lovastatin
Spheroids (20 mg total protein) were treated with final concen-
trations of 0, 1 or 10 μM lovastatin, 0.5% DMSO in DMEM for
either 30 min or 18 h in 10 ml bioreactors.
Cholesterol synthesis was measured by then adding 7 μCi
ml−1 [1–14C]-sodium acetate (Perkin Elmer, cat. no.:
NEC084H001MC) to triplicate 3D cultures in bioreactors and
incubating for 4 h. The cholesterol content of the individual
samples was related to their total protein content determined
from a small sample of the NaOH spheroid lysate.7
Data and statistical analysis
In all assays, except for gene expression, data were normalized
with reference to the amount of protein present, either deter-
mined directly where possible or by estimation when a direct
determination was not possible. A single HepG2/C3A cell was
assumed to contain 0.2 ng protein.
For gene expression normalization was performed using
geometric mean expression of housekeeping genes GUSB,
H6PD and ALAS1: ΔCq = Cq gene of interest − Cq geomean
Housekeepers. The Relative Quantification methodology (ΔCq)
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was used to calculate expression changes over time relative to
day 21.
For the statistical analysis of the eﬀect of glucose concen-
tration and lovastatin treatment, the two-tailed Student’s t-test
was used. For analysis of variance of cholesterol synthesis at
the diﬀerent time points, one-way analysis of variance (ANOVA)
with Tukey error protection was used. For analysis of variance
of glycogen synthesis stimulated by insulin at the diﬀerent
time points two-way ANOVA was performed. Analyse-it Method
Evaluation Tool version 2.12 by Analyse-it Software, Ltd was
used to aid statistical analysis.
Results
The aim of this study was to determine whether hepatocytes
cultured as 3D spheroids could stably maintain their function-
ality over 3 weeks after the recovery transition and could stably
respond to pharmacological treatment and physiological
stimulation. For this reason we examined a series of cellular
functions specific to hepatocytes.
Growth rate
Growth rate of the spheroids was evaluated by following the
morphological changes and size increase until day 42. The
averaged starting size for the spheroids was 200 μm on day 0,
900 μm on day 21 and 1400 μm on day 42 (Fig. 1A–D). To
provide a more accurate evaluation of the growth rate, protein
content was measured. As shown in Fig. 1E the doubling time
increased from day 21 to day 42 showing that the cell growth
rate was slowing down.
Spheroid viability
ATP and adenylate kinase levels were followed to assess the via-
bility of the spheroids and measurements normalized per
microgram of protein to correct for increases in cell numbers.
During the first 21 days the amount of ATP increased.
Thereafter the ATP levels stabilised and remained constant
(Fig. 2A). The data for adenylate kinase showed that the per-
centage of dead cells is also essentially constant (Fig. 2B).
Both assays thus indicate that the viability of the cultures
between day 21 and 42 remains constant, illustrating that the
falling growth rate was not due to a reduction in viability.
Basal 3D spheroids functionality
To assess the functionality of the spheroids between day 21
and day 42, we selected three physiological functions of hep-
atocytes: glucose metabolism, cholesterol synthesis and urea
production. These analyses were carried out at intervals during
the 3 week study (typically at day 21, 28, 35 and 42 post culture
initiation). All analyses were normalised to the amount of
protein present in the samples. Measurements of cholesterol
and urea metabolism were non-invasive and thus could be per-
formed repeatedly on the same culture while the glucose
metabolism assay required separate cultures for each data
point.
Glucose metabolism
The rate of glycogen synthesis was assayed at diﬀerent concen-
trations of glucose in the medium. Spheroids were provided
with radioactive glucose (at a constant specific activity) and
glycogen synthesis was quantitated by measuring the amount
of radioactive glucose incorporation into glycogen. The results
(Fig. 3) showed that glycogen synthesis was roughly pro-
portional to the increase in glucose concentrations in the
media, with a steady increase from 5.5 to 25 mM.
Urea and cholesterol synthesis and secretion
Two important functions of the liver are the synthesis and
secretion of urea and cholesterol. Spent media was assayed for
Fig. 1 Growth of C3A spheroids during 42 days. (A–D) Photomicrographs of
spheroid cultures at 21, 28, 35 and 42 days respectively. The bar in (A) indicates
1 mm. (E) Cell growth in 3D cultures. Spheroids were cultivated in the Proto-
Tissue™ bioreactor. Duplicate bioreactors were terminated at diﬀerent times
and the protein content of on average 170 spheroids was estimated at each
time point for each bioreactor using the relationship between their shadow area
and protein content. The growth rate was determined from the incremental
increase in the total protein content of the bioreactor. The error bars indicating
standard deviation are in some cases smaller than the symbol.
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urea or cholesterol secretion at multiple times during the
study period. The amount of urea produced was somewhat
variable but still appeared essentially constant at about 1.6 ±
0.35 mM per day per gTP (grams of total cellular protein) aver-
aged over the observation period of 21 days (Fig. 4A). The gene
expression level for arginase (Arg1), the enzyme catalysing the
hydrolysis of arginine to ornithine and urea, was correspond-
ingly stable over the 3 weeks period (Table 1). As can be seen
from Fig. 4B, the amount of cholesterol secreted was reason-
ably constant at about 30 μg per day per gram of cellular
protein. This is consistent with the observation that the gene
expression levels of HMG-CoAR were stable over the 3 weeks
(Table 1).
It is important to note that the steady state rates of syn-
thesis for both urea and cholesterol were significantly above
the synthesis rates seen during the first few days of culture.
Gene expression
Hepatocytes in the liver are the primary site for the synthesis
of many of the most abundant proteins in the blood. Gene
expression analysis performed here confirmed that RNAs for
several of these proteins (albumin, factor VII, the fatty acid
binding protein and transferrin) were all expressed at mode-
rate or high levels. In addition, the expression of several genes
related to key pathways in hepatocytes functionality was evalu-
ated over the 3 weeks period (Table 1). All genes showed detect-
able expression levels and maintained a stable pattern from
day 21 to day 42 (data normalized to the expression level on
day 21).
3D spheroids functionality under physiological and
pharmacological stimulations
Glycogen synthesis upon insulin stimulation. Glycogen
storage in hepatic spheroids is regulated by a number of
factors including glucose concentration and hormone treat-
ment. Therefore we evaluated whether the increase in glycogen
synthesis in response to insulin stimulation was stable over 3
weeks. We first evaluated the gene expression levels of glyco-
gen synthase (the enzyme catalysing the addition of UDP-
glucose to (1,4)-alpha-D-glucose multimers) and of GLUT2
(SLC2A2, the transporter mediating the entry of glucose in the
hepatocytes) and observed that these were stable over the
3 weeks (Table 1). Then we evaluated the response of the
spheroids to insulin at day 21, 28, 35 and 42 post culture
initiation at the two lower glucose concentrations tested.
Those concentrations correspond to glucose values observed
in normoglycemic (5.5 mM) and hyperglycemic (11.1 mM) con-
ditions in man. Fig. 5 illustrates that the addition of 100 nM
insulin to the hepatocyte spheroids cultured in 5.5 mM
glucose caused a statistically significant increase in glycogen
synthesis (70%, 21%, 37% and 50% after respectively 21, 28,
Fig. 2 Viability of spheroids in long term cultures. (A) The total amount of ATP present in quadruplicate 3D cultures. Data were normalised to mM per day per
gram of total cellular protein (gTP). (B) The percentage of dead cells present in quadruplicate 3D cultures, as estimated by adenylate kinase release. Error bars indi-
cate standard deviation and are in some cases smaller than the symbol.
Fig. 3 Glycogen synthesis in spheroids. Relationship between the glucose con-
centration in the growth medium and glyconeogenesis in quadruplicate
samples of 21 day old spheroids. Error bars indicate standard deviation.
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35 and 42 days (Fig. 5A–D respectively)) when assessed using
the Student’s t-test (p = 0.02, 0.02, 0.03 and 0.04 respectively,
indicated in the figure by the * over the grey bars). Similar
experiments carried out in parallel where the spheroids were
grown in 11.1 mM glucose caused no increase in glycogen syn-
thesis (p = 0.58, 0.80, 0.97 and 0.70 respectively).
A comparison of the increase in glycogen synthesis compar-
ing spheroids grown in 11.1 compared to 5.5 mM glucose
showed that the diﬀerence was statistically significant
(Student’s t-test) for the 21, 35 and 42 day cultures (p = 0.03,
0.01 and 0.01 respectively, indicated in the figure by the * over
the black bars) but not at 28 days (p = 0.12).
Lovastatin inhibition of cholesterol synthesis. Lovastatin is
a competitive inhibitor of the HMG-CoAR and thus treatment
of the spheroids should result in a decrease in cholesterol syn-
thesis. Treatment of 21 and 42 day old spheroids with 0 and
Fig. 4 Urea and cholesterol production in long term spheroid cultures. The growth media was collected from duplicate ProtoTissue™ bioreactors, clariﬁed by
centrifugation and the amount of urea (A) or cholesterol (B) present quantitated at the times shown. Data were normalized to mM or μM per day per gram of total
cellular protein (gTP). The data from day 0 to day 21 for both urea and cholesterol were previously presented in ref. 4. Error bars indicate standard deviation and are
in some cases smaller than the symbol.
Table 1 Gene expression of selected liver speciﬁc genes in long term spheroid cultures. Gene expression was measured for selected genes which were speciﬁc or
important for liver function in 21, 28, 35 and 42 day old spheroids. The data are the median expression of 3 independent samples, normalized to geometric mean
of the housekeeping genes GUSB, H6PD, ALAS1; ddCT (gene of interest − geomean Housekeepers) and expressed as a percentage
Gene name Biological function
Normalized median
expression (at day 21)
Expression
categorya
Relative normalized expression %
(compared to day 21 = 100%)
Day 28 Day 35 Day 42
SLC2A2 (GLUT2) GS Glucose import and
glycogen synthesis
1.2 Medium 90 98 95
High 91 85 80
FBP1 Gluconeogenesis 4.8 Medium 81 75 92
G6PC −2.5 Medium 98 98 98
PCK2 −0.6 Medium 96 94 97
ARG1 Urea production 7.0 Low 87 93 90
HMGCR SLCO1B1 (OATP1B1) Cholesterol biosynthesis −1.8 Medium 96 91 97
Lovastatin transport −15.9 High 91 98 90
SLCO1A2 Bile acid import/export
and synthesis
−15.9 High 95 98 97
CYP7A1 6.6 Low 88 91 91
SLC10A1 12.0 Low 84 75 63
CYP3A4 Drug metabolism 10.2 Low 68 59 61
CYP1A1 Paracetamol detoxification 5.4 Medium 84 90 77
CYP1A2 4.6 Medium 95 89 90
ALB Liver specific genes −9.3 High 95 96 97
F7 0.9 Medium 94 97 89
FABP1 −5.6 High 94 98 89
TF −7.0 High 92 94 96
a For convenience they have been grouped into three expression groups: high: ΔCq (−16 ≤ x < −6); medium: ΔCq (−6 ≤ x < 6); low: ΔCq
(6 ≤ x < 16).
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10 μM lovastatin for 4.5 h resulted in a significant reduction in
the amount of [14C]-cholesterol synthesised from [14C]-acetic
acid (Table 2). This is consistent with the stable expression of
the transporter for lovastatin into the cells (SLCOB1) and of
the expression of HMG-CoAR. Treatment of the spheroids with
1 μM lovastatin for 22 h resulted in a stimulation of cholesterol
synthesis (Table 2). This is interpreted to be a homeostatic
recovery process following inhibition of cholesterol synthesis
(i.e. induction of cellular hypocholesterolemia) and the sub-
sequent inactivation or metabolism of the lovastatin allowing
the cells to recover from their deficit by overproduction of
cholesterol.
Discussion
Human hepatocytes cultures are commonly used in drug deve-
lopment for a range of functional assessments (ADME, meta-
bolic functions, biomarker and pathways analysis).
Nevertheless it is known that primary hepatocytes in culture
do not retain some of the key functions they exert in vivo using
the classical cell culture conditions.
The main diﬀerence between cells cultured using the classi-
cal culture conditions (in the bottom of microtitre plates,
flasks etc., i.e. ‘flat or 2D culture’ conditions) and spheroids
(true 3D culture) is the fact that the cells can grow undisturbed
in a 3D environment (i.e. without suﬀering damage by trypsi-
nisation), receive an active supply of nutrients as the growth
media ‘flows past’ and they can develop tight interactions with
other cells and recover functionality typical of normal hepato-
cytes. This allows the cells to develop several ultrastructural
and physiological features that do not normally have time to
develop when the same cells are grown in otherwise the same
conditions using classical cell and tissue culture procedures.
These features include tight junctions, microvillae, bile canali-
culae-like tubules, glycogen granules, urea and cholesterol
secretion. Judged by their morphologic appearance, growth
rate, the production of ATP, adenylate kinase, cholesterol and
urea, the spheroids need at least 18 days to recover.4 These
observations would be fully compatible with the recent report
that sandwich-cultured rat hepatocytes need 6 days to establish
cell polarity and bile canaliculi8 because in the spheroid
system presented here, the hepatocytes first have to synthesise
their own extracellular matrix (which is otherwise provided in
the sandwich-culture models) before they do the same.
The outstanding question examined in this report concerns
the functional stability of hepatocyte spheroids after the
recovery process and their reactivity to physiological and
Fig. 5 Eﬀect of insulin on glycogen synthesis in long term spheroid cultures. Quadruplicate spheroid cultures of diﬀerent ages (A: 21 days; B: 28 days; C: 35 days
and D: 42 days) were grown in the presence of either 5.5 or 11 mM glucose and treated or mock treated with 100 nM insulin. Results have been normalised to the
level of glycogen synthesis in the control mock-treated spheroids grown in 5.5 mM glucose. Error bars indicate standard deviation.
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pharmacological stimulations. In particular, we have investi-
gated basal 3D spheroid activities (cell growth and expression
of liver-specific genes) and four of the core functions per-
formed by the liver: glycogen synthesis and response to insulin
stimulation; urea production, cholesterol production and its
inhibition by lovastatin. In addition, we have measured the
expression of some key genes related to hepatocyte specific
functions. These results have shown that the features deve-
loped by the spheroids are stable for at least 21 days once they
have been established (i.e. spheroids are metabolically stable
from day 21 to 42 in culture). This period of stability is prob-
ably much longer because spheroids have been cultivated in
our laboratories without trypsinisation for up to 302 days (at
which time point the culture still looked perfectly healthy).
Cell growth and gene expression
The investigation of the basic functions of the 3D spheroid
system showed that between 21 and 42 days of culture the cells
are able to proliferate and maintain their viability. This is
particularly relevant because of the growing modality of the
cultures which may limit oxygen and nutrient availability
to the cells in the inner part of the spheroids and impact the
validity of the functional assessments.
In addition, gene expression analysis showed that the cells
in the 3D spheroids express a wide set of liver-specific pro-
teins, thus indicating that they are in a fully diﬀerentiated
state.
Finally, 3D spheroids also express genes of key pathways
related to liver functions, which make them amenable for
exploratory investigations such as biomarker discovery and
drug mode of action studies.
Glycogen synthesis
One of the primary functions of the liver is to assist in the
regulation of blood sugar by converting glucose to glycogen
(glycogenesis) at times when the blood sugar level is high and
convert it back again when blood sugar levels are low. The
anabolic synthesis is regulated in part by the hormone insulin
which is secreted into the blood stream from the pancreas
upon food intake. Glucose uptake into the liver is facilitated by
SLC2A2 (GLUT2, a passive, high capacity low-aﬃnity transpor-
ter) shown by gene expression to be expressed at expectable,
stable levels throughout the 21 day study period.9 Glucose is
then phosphorylated by the enzyme hexokinase, eﬀectively
trapping the glucose-6-phosphate inside the cell. In the liver,
glucokinase has a low aﬃnity for glucose (Km of about
10 mM), and is not inhibited by glucose-6-phosphate. This
allows hepatocytes to accumulate large amounts of glucose
6-phosphate when blood glucose concentrations are high.10 In
our spheroid cultures we indeed observed an increased glyco-
gen synthesis depending on the concentration of glucose in
the medium (from 5.5 to 25 mM). Once in the cells, glucose
can enter a number of metabolic pathways including glycogen
synthesis. We observed a stable pattern of expression of glyco-
gen synthase from day 21 to 42. In addition, we observed a
stable increase in glycogen synthesis in response to insulin at
5.5 mM glucose concentration in the medium. Insulin binding
regulates the glycogen production via the activation of protein
kinase β. This kinase indirectly induces the dephosphorylation
and activation of glycogen synthase (increasing the rate of
glycogen synthesis) and dephosphorylates and inactivates
glycogen phosphatase (decreasing the rate of glycogen break-
down).11 Interestingly, an increase in glycogen synthesis was
not observed at 11.1 mM glucose concentration in the
medium. It is tempting to speculate that the non-response to
insulin in conditions of high extracellular glucose mimics a
condition of relative insulin resistance as the one observed in
type 2 diabetes. However additional parameters (e.g. phos-
phorylation of insulin receptor and downstream factors)
should be evaluated to gather a more complete picture.
In addition to the reactivity of the system to insulin in
terms of glycogen synthesis, we evaluated the expression of key
genes in the gluconeogenesis pathway, such as glucose 6-phos-
phatase, fructose biphosphatase and phosphoenolpyruvate
Table 2 Inhibition of cholesterol synthesis in spheroids by lovastatin treatment. Triplicate spheroid cultures of diﬀerent ages were treated with 0, 1 or 10 μM lova-
statin for either 0.5 or 18 h, pulse fed with [1–14C]-sodium acetate for 4 h and then cholesterol production measured. Data were corrected for the total amount of
protein present and signiﬁcance determined using a two-tailed Student’s t-test
Spheroid age (days) Treatment (h)
Lovastatin
Student’s t-test
0 μM 10 μM
CPM SD CPM SD p
21 4.5 38 281 3068 462 113 0.002
42 4.5 37 557 7646 7452 11 939 0.020
Spheroid age (days) Treatment (h)
Lovastatin
Student’s t-test
0 μM 1 μM
CPM SD CPM SD p
35 22 56 077 16 810 110 636 19 185 0.020
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carboxykinase, and we observed a similar level of expression
from day 21 to 42, indicating the maintenance of gluconeo-
genic pathway over 3 weeks (Table 1).
Overall, our data indicate that the spheroids maintain their
functionality in glucose and glycogen metabolism from day 21
to 42. Our data are partially in contrast with a study by Dabos
et al., where they found significant changes in a number of
parameters (including glucose, lactate, pyruvate, amino acids,
urea and ethanol production) during a 21 day spheroid culture
of primary porcine hepatocytes. Interestingly they described a
progressive switch in the metabolism from anaerobic (and
active gluconeogenesis) to aerobic (with restricted gluconeo-
genesis) during days 7–10.12 The observed diﬀerences may
reflect intrinsic diﬀerences in growth potential between the
decline of primary cells and immortal cell lines in culture.
Urea
The urea cycle is the main pathway allowing the detoxification
from ammonia and it is one of the main functions of the liver.
One key enzyme of the urea cycle is arginase 1 (Arg1) that con-
verts arginine in ornithine and urea. In vivo, urea production
is in the region of 0.74 mM urea per day per gTP (grams of
total protein)4 and both primary hepatocytes and HepG2/C3A
cells have been shown to produce similar amounts (0.55 mM
per day per gTP13,14).
One key feature of hepatocytes cell lines grown in 2D
systems, such as HepG2 and HepG2/C3A cells, is that they
have lost the capability to detoxify ammonia, in that they have
a non-functional urea cycle (HepG2 cells do not express
Arg115), and the urea that they do produce (0.160 mM per day
per gTP) is produced via Arg2 (HepG2/C3A cells13,16). The level
of urea production of HepG2/C3A cells was shown to be sensi-
tive to glucose levels, being highest (1.7 mM per day per gTP)
in a glucose-free media.14 In our 3D spheroid system, urea pro-
duction between day 21 and 42 is in the range of 1.6 ±
0.35 mM per day per gTP. This system stably expresses Arg1 at
low levels, thus suggesting that ammonia detoxification may
be possible.
Cholesterol
Another of the essential functions of the liver is to produce
cholesterol. The liver synthesizes about 25% of the body’s
daily requirement,17 and this corresponds to a daily pro-
duction of about 5.5 μM per gram of hepatocyte protein.4
Cholesterol is used in part to maintain cell membrane fluidity
and in part as an essential precursor of a number of important
molecules such as steroid hormones, fat soluble proteins and
bile acids. Cholesterol is synthesised from acetate by several
steps, taking place in the endoplasmic reticulum and the mito-
chondria, in the mevalonate pathway. The first part of the reac-
tion pathway occurs in the cytosol, but the irreversible and rate
limiting step from 3-hydroxy-3-methylglutaryl-CoA (HMG CoA)
to mevalonate is catalysed by the HMG-CoA reductase
(HMG-CoAR). Because of this, compounds aﬀecting
HMG-CoAR activity are widely used in the clinic to regulate the
synthesis of cholesterol.17 The cholesterol lowering group of
drugs, the ‘statins’, resemble the HMG part of HMG-CoA and
have a much higher aﬃnity for the active site of the
HMG-CoAR, enabling them to act as competitive inhibitors.18
Furthermore, the mevalonate pathway is controlled by feed-
back inhibition of HMG-CoAR and HMG-CoA synthase by the
end product, cholesterol. This regulation is important for the
hepatocyte to balance the internal and external sources of
cholesterol in order to sustain mevalonate synthesis and at the
same time avoid steroid accumulation.19
Cholesterol synthesis was not stable and reached a peak at
around day 10 in Hep2 cells cultured for 21 days on alginate
spheroids.20 In our spheroid system, the cholesterol levels
appear constant between day 21 and day 42. Consistently,
HMG-CoAR gene expression levels do not change throughout
the three week period.
Out of the 12 transporters (SLCO1A2, SLCO2B1, SLCO1B1,
SLCO3A1, SLCO4A1, SLCO1B3, SLC22A7, SLC22A8, SLC22A1,
SLC10A1, SLC15A1, and SLC15A2) investigated in HepG2 cells,
Libra found 11 expressed. Of these, the gene expression of
SLCO1B1, SLCO3A1, and SLCO1B3 was greatly repressed, while
the expression of SLCO2B1, SLC22A7, and SLC22A8 was either
maintained or increased in HepG2 in comparison to their
expression in human liver.21 Currently it is not clear whether
the high expression of SLCO1A2 and SLCO1B1 seen here is a
specific diﬀerence between the HepG2 cells and HepG2/C3A or
whether the spheroid culture has induced their expression.
Several other transporters have also been shown to be
expressed and active in HepG2 and HepG2/C3A cell lines.
These include P-gp (MDR1 or ATPB1), and MRP2
(cMOAT),22–24 and several amino acid transporters (SLC7A11,
SLC1A4, and SLC3A2).25
Interestingly the increasing amounts of cholesterol seen
following the recovery period would be expected to induce an
increase in SCL10A1 and SCL22A1 (but not of SCLO1A2
(OATP1A2) or CYP3A4).26 This would be a logical preparation
for bile synthesis and secretion. The results observed here: low
expression of SCL10A1, CYP3A4 and high expression of
SCLO1A2 therefore present an incomplete picture.
It is interesting to note that the same HepG2/C3A cells,
which in 2D systems show several limitations (e.g. low choles-
terol production, no urea cycle, reduced cytochromes func-
tion), recover the functionality typical of human liver in the 3D
spheroid system.
Technical limitations of 3D spheroids
There are some technical limitations in working with our 3D
spheroid system. First of all the classical microtitre plates
format used with 2D systems is not applicable to the spher-
oids, thus implying a lower throughput of the experimental
setting. Second, the 3D spheroid system is less amenable to
microscopy and high content imaging as compared to 2D
systems, which makes the direct visualisation of cells or orga-
nelles more complicated.
Finally, a general limitation shared between our 3D spher-
oid system and other 3D and 2D systems that are composed of
primary hepatocytes or immortalized cell lines is that they do
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not capture the interactions with other relevant liver cell types,
such as Kupﬀer cells, stellate cells and endothelial cells, which
are functional partners of hepatocytes in the liver.
Nevertheless, the 3D spheroid system shows a number of
advantages that largely outweighs the limitations. First of all,
this culturing system allows HepG2/C3A cells to recover some
key functions that are typical of the liver and that are lost in
2D systems. Whether this is due to the resuming of the diﬀer-
entiation program or to the simple fact that cells can recover
undisturbed for a longer time is not clear at this point in time.
Certainly, using HepG2/C3A cells provides a practically unlim-
ited amount of identical starting material, which ensures a
greater biological homogeneity as compared to primary
hepatocytes.
Conclusions
Spheroids constructed from the human HepG2/C3A hepato-
cellular carcinoma cell line show a number of characteristics
on the ultrastructural, expression and functional levels, which
suggests that they mimic the function of the human liver and
that these attributes are reproducible and stable over at least
the 3 weeks used as the study period.
In addition, the 3D spheroid system allows the cells to be
functionally stable for several weeks (in a pilot study spheroids
were cultured for up to 302 days), thus enabling long-term
studies.
The low biological variability and the long-term stability
make this system particularly useful for the investigations of
the compounds mode of action, toxicology and for biomarker
discovery. Further developments (e.g. deep focus confocal
microscopy) and novel handling procedures will pave the way
for the introduction of 3D culture into the mainstream of
biology.
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